Adjuvant goserelin in premenopausal patients with early breast cancer : Results from the ZIPP study

Content Provider	Semantic Scholar
Author	Bauma, M. Hackshawe, A. Houghtona, J. Fornanderb, T. Nordenskjoldc, B. Nicoluccid, A. Sainsburya, R.
Copyright Year	2006
Abstract	The Zoladex In Pre-menopausal Patients (ZIPP) study was designed to determine whether addition of goserelin (‘Zoladex’) and/or tamoxifen to adjuvant therapy (radiotherapy and/ or chemotherapy), provided benefit to preor peri-menopausal women with operable, early breast cancer. A combined analysis of four randomised trials using a core protocol was performed. Patients (n = 2710) were randomised into a 2 · 2 factorial trial based on goserelin and tamoxifen (n = 1800) or randomised to receive goserelin or not (n = 910; some received elective tamoxifen) for 2 years. The analysis presented here compares women who did (n = 1354) or did not (n = 1356) receive goserelin. After a median follow-up of 5.5 years, goserelin provided a significant benefit for event-free survival (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.69, 0.92; P = 0.002) and overall survival (HR 0.81; 95% CI 0.67, 0.99; P = 0.038). Goserelin was well tolerated. These data show that the addition of goserelin to standard adjuvant therapy is more effective than standard therapy alone in pre-menopausal women with early breast cancer. 2006 Elsevier Ltd. All rights reserved.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://xuebalib.oss-cn-shanghai.aliyuncs.com/xuebalib.com.7922.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article